-
EP2783698
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2783698
| EP2783698 - Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 09.10.2015 Database last updated on 12.07.2024 | Most recent event Tooltip | 09.10.2015 | Application deemed to be withdrawn | published on 11.11.2015 [2015/46] | Applicant(s) | For all designated states ST VINCENT'S HOSPITAL SYDNEY LIMITED Centre for Immunology Victoria Street Sydney, NSW 2010 / AU | For all designated states Garvan Institute of Medical Research St. Vincent's Hospital 384 Victoria Street Darlinghurst, NSW 2010 / AU | [2014/40] | Inventor(s) | 01 /
Breit, Samuel Norbert 33 Carlotta Avenue Gordon, New South Wales 2072 / AU | 02 /
Brown, David Alexander 19 Tambourine Bay Road Lane Cove, New South Wales 2066 / AU | 03 /
Herzog, Herbert 17/318 Bondi Road Bondi, New South Wales 2026 / AU | 04 /
Lin, Shu 19 Water Street Lidcombe, New South Wales 2141 / AU | [2014/40] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2014/40] | Harding, Charles Thomas, et al D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 14169349.9 | 18.08.2008 | [2014/40] | Priority number, date | AU2007904412P | 16.08.2007 Original published format: AU 2007904412 P | [2014/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2783698 | Date: | 01.10.2014 | Language: | EN | [2014/40] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 02.09.2014 | Classification | IPC: | A61K38/19, G01N33/53, A61P3/04, G01N33/68 | [2014/40] | CPC: |
G01N33/6863 (EP,US);
A61K39/3955 (US);
A61K38/1841 (EP,US);
A61P1/14 (EP);
A61P13/12 (EP);
A61P25/00 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
G01N2333/495 (EP,US);
G01N2333/71 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2014/40] | Title | German: | Mittel und Verfahren zur Modulation von makrophagenhemmender Zytokin (MIC-1) Aktivität | [2014/40] | English: | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity | [2014/40] | French: | Agents et procédés pour moduler l'activité de la cytokine inhibitrice des macrophages (MIC-1) | [2014/40] | Examination procedure | 21.05.2014 | Examination requested [2014/40] | 02.04.2015 | Application deemed to be withdrawn, date of legal effect [2015/46] | 03.06.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2015/46] | Parent application(s) Tooltip | EP08782955.2 / EP2187933 | Fees paid | Renewal fee | 19.06.2014 | Renewal fee patent year 03 | 19.06.2014 | Renewal fee patent year 04 | 19.06.2014 | Renewal fee patent year 05 | 19.06.2014 | Renewal fee patent year 06 | 13.08.2014 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 31.08.2015 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2004056352 (SCIOS INC [US], et al) [A] 1-15 * p. 2, line 1 - p. 3, last line, claims 1-7 *; | [XA]WO2005099746 (ST VINCENTS HOSP SYDNEY [AU], et al) [X] 1-3,6-11,14,15 * p. 5, line 25 - p. 10, line 7 * [A] 4,5,12,13; | [A]US2007077598 (BREIT SAMUEL N [AU], et al) [A] 1-15 * p. 2, paragraph [0028] - p. 3, paragraph [0037] *; | [T] - SKIPWORTH R J E ET AL, "Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.", BRITISH JOURNAL OF CANCER 16 FEB 2010 LNKD- PUBMED:20104227, (20100216), vol. 102, no. 4, ISSN 1532-1827, pages 665 - 672, XP002607047 [T] 1-15 * abstract, pp. 668-669, paragraph "Relationship of MIC-1 with systemic inflammation and nutritional status", p. 670, paragraph "Discussion" * | [XP] - JOHNEN HEIKO ET AL, "Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1", NATURE MEDICINE, (200711), vol. 13, no. 11, ISSN 1078-8956, pages 1333 - 1340, XP002607045 [XP] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/NM1677 | [XP] - WAKCHOURE SAVITA ET AL, "Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.", THE PROSTATE 1 MAY 2009 LNKD- PUBMED:19152406, (20090501), vol. 69, no. 6, ISSN 1097-0045, pages 652 - 661, XP002607046 [XP] 1-15 * the whole document * | by applicant | US5225539 | WO2005099746 | - TISDALE, MJ, "Cachexia in cancer patients", NAT REV CANCER, (2002), vol. 2, pages 862 - 871 | - HUHMANN, MB; CUNNINGHAM, RS, "Importance of nutritional screening in treatment of cancer-related weight loss", LANCET ONCOL, (2005), vol. 6, doi:doi:10.1016/S1470-2045(05)70170-4, pages 334 - 343, XP004870910 DOI: http://dx.doi.org/10.1016/S1470-2045(05)70170-4 | - MARKS, DL; LING, N; CONE, RD, "Role of the central melanocortin system in cachexia", CANCER RES, (2001), vol. 61, pages 1432 - 1438 | - RUBIN, H, "Cancer cachexia: its correlations and causes", PROC NATL ACAD SCI, (2003), vol. 100, doi:doi:10.1073/pnas.0931260100, pages 5384 - 5389, XP009117770 DOI: http://dx.doi.org/10.1073/pnas.0931260100 | - RAIL, LC; ROUBENOFF, R, "Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions", RHEUMATOLOGY, (2004), vol. 43, pages 1219 - 1223 | - ANKER, SD; SHARMA, R, "The syndrome of cardiac cachexia", INT J CARDIOL, (2002), vol. 85, pages 51 - 66 | - BOOTCOV, MR ET AL., "MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-? superfamily cluster", PROC NATL ACAD SCI, (1997), vol. 94, doi:doi:10.1073/pnas.94.21.11514, pages 11514 - 11519, XP002180665 DOI: http://dx.doi.org/10.1073/pnas.94.21.11514 | - WELSH, JB ET AL., "Large-Scale Delineation of Secreted Protein Biomarkers Overexpressed in Cancer Tissue and Serum", PROC NATL ACAD SCI, (2003), vol. 100, doi:doi:10.1073/pnas.0530278100, pages 3410 - 3415, XP002993660 DOI: http://dx.doi.org/10.1073/pnas.0530278100 | - BUCKHAULTS, P ET AL., "Secreted and cell surface genes expressed in benign and malignant colorectal tumours", CANCER RES, (2001), vol. 61, pages 6996 - 7001, XP002960006 | - KOOPMANN,J ET AL., "Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and other Periampullary Cancers", CLIN CANCER RES, (2004), vol. 10, pages 2386 - 2392 | - BAUSKIN, AR ET AL., "The propetide mediates formation of stromal stores of proMIC-1: Role in determining prostate cancer outcome", CANCER RES, (2005), vol. 65, pages 2330 - 2336 | - HSIAO, EC ET AL., "Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury", MOL CELL BIOL, (2000), vol. 20, doi:doi:10.1128/MCB.20.10.3742-3751.2000, pages 3742 - 51, XP002525556 DOI: http://dx.doi.org/10.1128/MCB.20.10.3742-3751.2000 | - SCHOBER. A ET AL., "Expression of growth differentiation factor-15/ macrophage inhibitory cytokine-(GDF-15/MIC-1) in the perinatal, adult, and injured rat brain", J OMP NEUROL, (2001), vol. 439, pages 32 - 45 | - BAUSKIN, AR ET AL., "Role of MIC-1 in Tumourigenesis and Diagnosis of Cancer", CANCER RES, (2006), vol. 66, pages 4983 - 4986 | - FAIRLIE, WD ET AL., "Epitope mapping of the Transforming Growth Factor-? superfamily protein, Macrophage Inhibitory Cytokine-1 (MIC-1): Identification of at least five distinct epitope specificities", BIOCHEMISTRY, (2001), vol. 40, doi:doi:10.1021/bi001064p, pages 65 - 73, XP055089324 DOI: http://dx.doi.org/10.1021/bi001064p | - BROWN, DA ET AL., "Concentration in plasma of macrophage inhibitory cytokine-1 and the risk of cardiovascular events in women", LANCET, (2002), vol. 359, doi:doi:10.1016/S0140-6736(02)09093-1, pages 2159 - 2163, XP004798276 DOI: http://dx.doi.org/10.1016/S0140-6736(02)09093-1 | - CHALLET, E. ET AL., "Involvement of corticosterone in the fasting-induced rise in protein utilization and locomotor activity", PHARMACOL BIOCHEM BEHAV, (1995), vol. 50, pages 405 - 412 | - KAMEL, HK; MAAS, D; DUTHIE, EH, "Role of hormones in the pathogenesis and management of sarcopenia", DRUGS AGING, (2002), vol. 19, pages 865 - 877 | - ROSEN, CJ ET AL., "Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program", BONE, (2004), vol. 35, doi:doi:10.1016/j.bone.2004.07.008, pages 1046 - 1058, XP004638889 DOI: http://dx.doi.org/10.1016/j.bone.2004.07.008 | - PARK, S; SOHN, S; KINEMAN, RD, "Fasting-induced changes in the hypothalamic-pituitary-GH axis in the absence of GH expression: lessons from the spontaneous dwarf rat", JENDOCRINOL, (2004), vol. 180, pages 369 - 378 | - LEWITT, MS, "Responses of insulin-like growth factor (IGF)-I and IGF-binding proteins to nutritional status in peroxisome proliferator-activated receptor-alpha knockout mice", GROWTH HORM IGF RES, (2001), vol. 11, doi:doi:10.1054/ghir.2001.0247, pages 303 - 313, XP009083202 DOI: http://dx.doi.org/10.1054/ghir.2001.0247 | - FRIEDL, KE ET AL., "Endocrine markers of semistarvation in healthy lean men in a multistressor environment", JAPPL PHYSIOL, (2000), vol. 88, pages 1820 - 1830 | - PFITZENMAIER, J. ET AL., "Elevation of cytokine levels in cachectic patients with prostate carcinoma", CANCER, (2003), vol. 97, pages 1211 - 1216 | - THOMPSON, IM ET AL., "Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower", JAMA, (2005), vol. 294, pages 66 - 70 | - NAYLOR, JL ET AL., "Further evidence that the blood/brain barrier impedes paraquat entry into the brain", HUMAN & EXPERIMENTAL TOXICOLOGY, (1995), vol. 14, pages 587 - 594 | - KARL, T. ET AL., "Y1 receptors regulate aggressive behavior by modulating serotonin pathways", PROC. NATL. ACAD. SCI, (2004), vol. 101, pages 12742 - 12747 | - BOURET, S. ET AL., "Formation of Projection Pathways from the Arcuate Nucleus of the Hypothalamus to Hypothalamic Regions Implicated in the Neural Control of Feeding Behavior in Mice", J NEUROSCI, (2004), vol. 24, pages 2797 - 2805 | - SAINSBURY, A; SCHWARZER, C; COUZENS, M; HERZOG, H, "Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob.mice", DIABETES, (2002), vol. 51, pages 3420 - 3427 | - KOVESDY, C. P.; ANDERSON, J. E.; KALANTAR-ZADEH, K., "Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome", JAM SOC NEPHROL, (2007), vol. 18, pages 304 - 311 | - APPLE, FS.; MURAKAMI, MM.; PEARCE, LA.; HERZOG, CA, "Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease", CIRCULATION, (2002), vol. 106, pages 2941 - 2945 | - LEE, DH. ET AL., "Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system", CANCER RES, (2003), vol. 63, no. 15, pages 4648 - 4655 | - MOORE, AG ET AL., "TGF-P superfamily cytokine MIC- is present in high concentrations in the serum of pregnant women", J CLIN ENDOCRINOL METAB, (2000), vol. 85, pages 4781 - 4788 | - WOLLMAN, W ET AL., "The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells", CARCINOGENESIS, (2005), vol. 26, no. 5, pages 900 - 907 | - DACOSTA BYFIELD, S. ET AL., "SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors, ALK4, ALK5 and ALK7", MOL PHARMACOL, (2004), vol. 65, doi:doi:10.1124/mol.65.3.744Cit, pages 744 - 752, XP055096104 DOI: http://dx.doi.org/10.1124/mol.65.3.744Cit | - BONNIAUD, P ET AL., "Progressive transforming growth factor ?1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor", AM JRESPIR CRIT CARE MED, (2005), vol. 171, doi:doi:10.1164/RCCM.200405-6120C, pages 889 - 898, XP002534045 DOI: http://dx.doi.org/10.1164/RCCM.200405-6120C | - DE GOUVILLE, AC ET AL., "Inhibition ofTGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis", BR J PHARMACOL, (2005), vol. 145, doi:doi:10.1038/sj.bjp.0706172, pages 166 - 177, XP055096102 DOI: http://dx.doi.org/10.1038/sj.bjp.0706172 | - KONRAD, L ET AL., "Alternative splicing of TGF-betas and their high-affinity receptors TpRI, T?RII and TpRIII (betaglycan) reveal new variants in human prostatic cells", BMC GENOMICS, (2007), vol. 8, page 318 |